-
Mashup Score: 2NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay - 10 day(s) ago
Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations. This study, inspired by the success of PARP inhibitors in metastatic settings and neoadjuvant successes in other cancers, aims to address the aggressive nature of BRCA-mutated prostate cancer earlier in the disease course. With a…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay - 1 month(s) ago
Rana McKay discusses the NePtune study, investigating PARP inhibitors as a neoadjuvant treatment for prostate cancer patients with BRCA1/2 mutations. This study, inspired by the success of PARP inhibitors in metastatic settings and neoadjuvant successes in other cancers, aims to address the aggressive nature of BRCA-mutated prostate cancer earlier in the disease course. With a…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
The #NePtune trial: Evaluating neoadjuvant PARP inhibition in BRCA-mutated #ProstateCancer. @DrRanaMcKay @UCSanDiego and @CaPsurvivorship @DanaFarber discuss the aggressive nature of BRCA-mutated PCa earlier in the disease course > https://t.co/Lqanr1Nhqk https://t.co/0eHfl33SSk